Overview

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate